What are the implications of adjuvant therapy data on biomarker evaluation?

touchMDT for touchONCOLOGY Listen to a medical oncologist and a pathologist discuss the benefits of biomarker testing in early and locally advanced NSCLC. The multidisciplinary team Medical oncologist: Dr David Planchard, France  Molecular pathologist: Prof. Albrecht Stenzinger, Germany This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/evolving-role-mdt-early-nsclc/